Outcomes of patients receiving clopidogrel prior to cardiac surgery

András Vorobcsuk, D. Aradi, Klára Farkasfalvi, I. Horváth, A. Komócsi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Clinical impact of the concomitant clopidogrel therapy on clinical outcomes in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically analyze outcomes in clopidogrel-treated patients undergoing cardiac operations to achieve greater statistical power and to define precise effect-estimates. Methods: PubMed and Central databases were searched for relevant studies published between January 2001 and May 2010. The main outcome measures were the rates of red blood cell (RBC) transfusion, reoperation, myocardial infarction and postoperative mortality. The outcome parameters were pooled with the random-effect model via generic-inverse variance-weighting. Results: Twenty studies comprising a total number of 23,668 patients were analyzed. Pooled analysis revealed that the administration of clopidogrel had a higher risk for postoperative mortality (OR: 1.24; 95% CI: 1.03-1.49, p = 0.03) that was consistent among studies. The rates of myocardial infarction were similar between groups. Clopidogrel-exposed patients were associated with a significantly higher rate of RBC transfusion (OR: 1.82; 95% CI: 1.40-2.37; p <0.00001) and reoperation (OR: 2.15; 95% CI: 1.38-3.34; p <0.00001), although there was a marked heterogeneity among studies. According to subgroup analysis the mortality and the rates of transfusions were higher in studies in which clopidogrel was not discontinued 5 days prior to surgery, while the higher risk for reoperation was only apparent in studies published before 2006. Conclusion: Meta-analysis of observational studies demonstrated that concomitant treatment with clopidogrel before cardiac surgery is associated with a significant risk of bleeding-related complications and with a higher mortality.

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalInternational Journal of Cardiology
Volume156
Issue number1
DOIs
Publication statusPublished - Apr 5 2012

Fingerprint

clopidogrel
Thoracic Surgery
Reoperation
Erythrocyte Transfusion
Mortality
Myocardial Infarction
PubMed
Observational Studies
Meta-Analysis
Outcome Assessment (Health Care)
Databases
Hemorrhage

Keywords

  • Clopidogrel
  • Complications
  • Mortality
  • Outcomes
  • Surgery
  • Transfusion

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Outcomes of patients receiving clopidogrel prior to cardiac surgery. / Vorobcsuk, András; Aradi, D.; Farkasfalvi, Klára; Horváth, I.; Komócsi, A.

In: International Journal of Cardiology, Vol. 156, No. 1, 05.04.2012, p. 34-40.

Research output: Contribution to journalArticle

@article{03094e73b72d47b686ed6f158955ffbc,
title = "Outcomes of patients receiving clopidogrel prior to cardiac surgery",
abstract = "Background: Clinical impact of the concomitant clopidogrel therapy on clinical outcomes in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically analyze outcomes in clopidogrel-treated patients undergoing cardiac operations to achieve greater statistical power and to define precise effect-estimates. Methods: PubMed and Central databases were searched for relevant studies published between January 2001 and May 2010. The main outcome measures were the rates of red blood cell (RBC) transfusion, reoperation, myocardial infarction and postoperative mortality. The outcome parameters were pooled with the random-effect model via generic-inverse variance-weighting. Results: Twenty studies comprising a total number of 23,668 patients were analyzed. Pooled analysis revealed that the administration of clopidogrel had a higher risk for postoperative mortality (OR: 1.24; 95{\%} CI: 1.03-1.49, p = 0.03) that was consistent among studies. The rates of myocardial infarction were similar between groups. Clopidogrel-exposed patients were associated with a significantly higher rate of RBC transfusion (OR: 1.82; 95{\%} CI: 1.40-2.37; p <0.00001) and reoperation (OR: 2.15; 95{\%} CI: 1.38-3.34; p <0.00001), although there was a marked heterogeneity among studies. According to subgroup analysis the mortality and the rates of transfusions were higher in studies in which clopidogrel was not discontinued 5 days prior to surgery, while the higher risk for reoperation was only apparent in studies published before 2006. Conclusion: Meta-analysis of observational studies demonstrated that concomitant treatment with clopidogrel before cardiac surgery is associated with a significant risk of bleeding-related complications and with a higher mortality.",
keywords = "Clopidogrel, Complications, Mortality, Outcomes, Surgery, Transfusion",
author = "Andr{\'a}s Vorobcsuk and D. Aradi and Kl{\'a}ra Farkasfalvi and I. Horv{\'a}th and A. Kom{\'o}csi",
year = "2012",
month = "4",
day = "5",
doi = "10.1016/j.ijcard.2010.10.034",
language = "English",
volume = "156",
pages = "34--40",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Outcomes of patients receiving clopidogrel prior to cardiac surgery

AU - Vorobcsuk, András

AU - Aradi, D.

AU - Farkasfalvi, Klára

AU - Horváth, I.

AU - Komócsi, A.

PY - 2012/4/5

Y1 - 2012/4/5

N2 - Background: Clinical impact of the concomitant clopidogrel therapy on clinical outcomes in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically analyze outcomes in clopidogrel-treated patients undergoing cardiac operations to achieve greater statistical power and to define precise effect-estimates. Methods: PubMed and Central databases were searched for relevant studies published between January 2001 and May 2010. The main outcome measures were the rates of red blood cell (RBC) transfusion, reoperation, myocardial infarction and postoperative mortality. The outcome parameters were pooled with the random-effect model via generic-inverse variance-weighting. Results: Twenty studies comprising a total number of 23,668 patients were analyzed. Pooled analysis revealed that the administration of clopidogrel had a higher risk for postoperative mortality (OR: 1.24; 95% CI: 1.03-1.49, p = 0.03) that was consistent among studies. The rates of myocardial infarction were similar between groups. Clopidogrel-exposed patients were associated with a significantly higher rate of RBC transfusion (OR: 1.82; 95% CI: 1.40-2.37; p <0.00001) and reoperation (OR: 2.15; 95% CI: 1.38-3.34; p <0.00001), although there was a marked heterogeneity among studies. According to subgroup analysis the mortality and the rates of transfusions were higher in studies in which clopidogrel was not discontinued 5 days prior to surgery, while the higher risk for reoperation was only apparent in studies published before 2006. Conclusion: Meta-analysis of observational studies demonstrated that concomitant treatment with clopidogrel before cardiac surgery is associated with a significant risk of bleeding-related complications and with a higher mortality.

AB - Background: Clinical impact of the concomitant clopidogrel therapy on clinical outcomes in patients undergoing cardiac surgery is unclear. We aimed to pool and systematically analyze outcomes in clopidogrel-treated patients undergoing cardiac operations to achieve greater statistical power and to define precise effect-estimates. Methods: PubMed and Central databases were searched for relevant studies published between January 2001 and May 2010. The main outcome measures were the rates of red blood cell (RBC) transfusion, reoperation, myocardial infarction and postoperative mortality. The outcome parameters were pooled with the random-effect model via generic-inverse variance-weighting. Results: Twenty studies comprising a total number of 23,668 patients were analyzed. Pooled analysis revealed that the administration of clopidogrel had a higher risk for postoperative mortality (OR: 1.24; 95% CI: 1.03-1.49, p = 0.03) that was consistent among studies. The rates of myocardial infarction were similar between groups. Clopidogrel-exposed patients were associated with a significantly higher rate of RBC transfusion (OR: 1.82; 95% CI: 1.40-2.37; p <0.00001) and reoperation (OR: 2.15; 95% CI: 1.38-3.34; p <0.00001), although there was a marked heterogeneity among studies. According to subgroup analysis the mortality and the rates of transfusions were higher in studies in which clopidogrel was not discontinued 5 days prior to surgery, while the higher risk for reoperation was only apparent in studies published before 2006. Conclusion: Meta-analysis of observational studies demonstrated that concomitant treatment with clopidogrel before cardiac surgery is associated with a significant risk of bleeding-related complications and with a higher mortality.

KW - Clopidogrel

KW - Complications

KW - Mortality

KW - Outcomes

KW - Surgery

KW - Transfusion

UR - http://www.scopus.com/inward/record.url?scp=84858070694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858070694&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2010.10.034

DO - 10.1016/j.ijcard.2010.10.034

M3 - Article

VL - 156

SP - 34

EP - 40

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -